CoChat

Velour trial biomarkers update: Impact of RAS, BRAF, and sidedness on aflibercept activity.

Wirapati, Pratyaksha, Pomella, Valentina, Vandenbosch, Ben, Kerr, Peter, Maiello, Evaristo, Jeffery, Grahame Mark, Curca, Razvan-Ovidiu D., Karthaus, Meinolf, Bridgewater, John A., Mihailov, Anca C., Kiss, Igor, Merino, Sandra, McKendrick, Joseph James, Saridaki, Zacharenia, Sagaert, Xavier JA, Tejpar, Sabine · 2017 · Journal of Clinical Oncology
Cited by 56

The DOI matches its Crossref record.

Abstract

3538 Background: Addition of (ziv)-aflibercept (A) to FOLFIRI in second-line therapy for metastatic colorectal cancer (CRC) has been shown to be beneficial in phase III VELOUR trial (NCT00561470). A follow-up study (NCT01754272) was undertaken to acquire tumor samples for biomarker analyses and identify subgroups of patients with differential treatment effects. The primary results assessing efficacy according to well-established CRC subgroups defined by RAS, BRAF status and sidedness are reported here. Methods: Tissue specimens were collected for 666 patients from 1226 ITT pts. Suitable specimens were assayed for somatic mutation using NGS targeting extended RAS and BRAF genes. NGS assays with no missing values were obtained for 482 pts. Affymetrix gene chip technology was used for whole-transcriptome profiling; sidedness was extracted from available pathological reports. Differences between subgroups were assessed by interaction analysis. Results: The treatment effects on overall survival (OS) for the 482 pts is still significant HR=0.80 (CI 0.65-0.99), and similar to the ITT (n=1226) results (HR=0.82, CI 0.71-0.93). Two established ways of defining mutations (traditional KRAS exon 2 and extended RAS using NGS) show a trend for a differential effect across mutation groups.(see table for OS). Interestingly, BRAF mutants (which are all RAS wild type) show a trend for better outcome Same is seen for PFS and RR. Sidedness did not affect efficacy (HR: 0.83 (0.63- 1.1) for left and HR: 0.83 (0.54-1.3) for right. Conclusions: None of the mutations subgroup results shows significant interaction, although the ratios of treatment HR favor RAS wild types. Similar trends were observed in published trials with bevacizumab or ramucirumab. Sanofi supported this ISS. Clinical trial information: NCT01754272. [Table: see text]

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2017.35.15_suppl.3538

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 56

Metadata

Authors
Wirapati, P., Pomella, V., Vandenbosch, B., Kerr, P., Maiello, E., Jeffery, G. M., Curca, R.-O. D., Karthaus, M., Bridgewater, J. A., Mihailov, A. C., Kiss, I., Merino, S., McKendrick, J. J., Saridaki, Z., Sagaert, X. J., & Tejpar, S.
Venue
Journal of Clinical Oncology
Published
2017-05-20
Volume
35
Issue
15_suppl
Pages
3538-3538
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W4246064222
Cited by
56
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Velour trial biomarkers update: Impact of RAS, BRAF, and sidedness on aflibercept activity. https://app.cochat.ai/papers/10.1200/jco.2017.35.15_suppl.3538
The paper
Wirapati, P., Pomella, V., Vandenbosch, B., Kerr, P., Maiello, E., Jeffery, G. M., Curca, R.-O. D., Karthaus, M., Bridgewater, J. A., Mihailov, A. C., Kiss, I., Merino, S., McKendrick, J. J., Saridaki, Z., Sagaert, X. J., & Tejpar, S. (2017). Velour trial biomarkers update: Impact of RAS, BRAF, and sidedness on aflibercept activity. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2017.35.15_suppl.3538

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.